Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Glabellar Frown Lines Clinical Trial

Official title:

A Randomized, Parallel-Group Study on the Duration Response of Highly Concentrated On Label Dose (COLD) of Jeuveau® Compared to the On Label Dose and Concentration (OLD) in Subjects With Moderate to Severe Dynamic Glabellar Lines

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05129319
• Other study ID #: CTBH-03-2021
• Status: Completed
• Phase: Early Phase 1
• Start date: December 16, 2021
• Est. completion date: June 15, 2023

Study information

• Verified date: March 2022
• Source: Clinical Testing of Beverly Hills
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

Description:

This study involves a blinded, randomized, parallel-group design. The aim of this study is to evaluate the duration response of Jeuveau in subjects with moderate to severe dynamic glabellar lines at the approved on-label dose of 20 U, however comparing the use of highly Concentrated On Label Dose (COLD) to the On Label Dose and concentration (OLD). The COLD concentration is defined as 4 Units per 0.02 mL and the OLD concentration is defined as 4 Units per 0.1 mL.

The total Jeuveau dose will be 20U divided into 5 injections for both study groups. However, the injection volume will differ for the two study groups, such that the OLD (4 U per 0.1 mL) group will receive a total of 0.5 mL and the COLD (4 U per 0.02 mL) group will receive a total of 0.1mL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 15, 2023
• Est. primary completion date: June 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years of age at the time of signing the informed consent.

• Overtly healthy as determined by medical evaluation (includes: medical history, physical examination, and vital signs).

• Subjects have moderate or severe dynamic glabellar lines on maximum frown as assessed with the Evolus GLS with photonumeric guide.

• Female sex.

• Female subjects willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. A female subject is eligible to participate if she is not pregnant (has a negative urine pregnancy result at Day 1 prior to treatment), is not breastfeeding, and at least one of the following conditions applies: 1)Not a female of childbearing potential OR 2) A female of childbearing potential who agrees to follow the contraceptive guidance in Appendix 4 during the study.

• Capable of giving signed informed consent as described in Appendix 2, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

• Written informed consent from the subject has been obtained prior to any study-related procedures.

• Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information)

• Able, as assessed by the blinded evaluating investigator, and willing to follow study instructions and likely to complete all required study visits.

Exclusion Criteria:

• Brow or eyelid ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or an inability to substantially lessen upper facial rhytides, even by physically spreading them apart.

• Facial asymmetry including, in the opinion of the investigator, significant asymmetry with active contraction or at rest of the frontalis muscle.

• Medical condition that may increase the subject's risk of exposure to botulinum toxin, including diagnosed myasthenia gravis, Lambert-Eaton Syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.

• Profound atrophy/excessive weakness of muscles in target areas of injection.

• History of facial nerve palsy.

• Infection at the injection site or systemic infection.

• Presence of inflammation at the proposed injection site.

• Previous cosmetic surgery to the upper face (eg, periorbital surgery, brow lift, eyelid or eyebrow surgery), tissue grafting, or tissue augmentation with silicone or fat or other permanent fillers, or planning a facial cosmetic procedure during the study period.

• Subjects have been treated in the upper face (forehead lines, glabellar lines, crow's feet lines) within 1 year prior to the Baseline/Day 1 Visit with botulinum toxin therapy of any serotype.

• Noncompliance with the proper washout periods for prohibited medications/procedures.

• Subjects on topical retinoid therapy and/or topical hormone cream applied to the face, who have not been on a consistent dose regimen for at least 6 months prior to enrollment and who are unable to maintain a consistent dose regimen during the study.

• Oral retinoid therapy within 1 year prior to study enrollment.

• Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.

• Females who are pregnant, breastfeeding, or planning a pregnancy during the study

• Females of childbearing potential not using a reliable means of contraception (see Appendix 4 for definition and acceptable methods of contraception).

• Known allergy or sensitivity to the study treatment or its components.

• Known immunization or hypersensitivity to any botulinum toxin serotype.

• Prior exposure to or anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment).

• Evidence of recent alcohol or drug abuse.

• The subject has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Related Conditions & MeSH terms

• Glabellar Frown Lines

Intervention

Drug:
• prabotulinumtoxinA
Injection of glabellar rhytids

Locations

Country	Name	City	State
United States	Clinical Testing of Beverly Hills	Encino	California

Sponsors (2)

Lead Sponsor	Collaborator
Clinical Testing of Beverly Hills	Evolus, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004 Nov;114(6 Suppl):1S-22S. doi: 10.1097/01.PRS.0000144795.76040.D3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Duration	Time to return to baseline Glabellar Line Scale (GLS) score at maximum frown, as assessed by the blinded evaluating investigator.; The Glabellar Line Scale (GLS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.	270 days
Secondary	Investigator Live Assessment (Dynamic)	Responder rate at each visit on the Glabellar Line Scale (GLS) at maximum frown, as assessed by the blinded evaluating investigator.; The responder rate is defined as the proportion of subjects maintaining a greater than or equal to 1 point improvement on the FWS.; The Glabellar Line Scale (GLS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.	270 days
Secondary	Subject Self Assessment (Dynamic)	Responder rate at each visit on the Glabellar Line Scale (GLS) at maximum frown, as assessed by the subject.; The Glabellar Line Scale (GLS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.	270 days
Secondary	Investigator Live Assessment (At Rest)	Responder rate at each visit on the Glabellar Line Scale (GLS) at rest, as assessed by the blinded evaluating investigator.; The Glabellar Line Scale (GLS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.	270 days
Secondary	Subject Self Assessment (At Rest)	Responder rate at each visit on the Glabellar Line Scale (GLS) at rest, as assessed by the subject.; The Glabellar Line Scale (GLS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.	270 days
Secondary	Change from Baseline Score	Change from baseline in mean Glabellar Line Scale (GLS) score at maximum frown, as assessed by the blinded evaluating investigator, at each visit.; The Glabellar Line Scale (GLS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.	270 days
Secondary	Change in Frontalis Function	Percentage of subjects with weakening of frontalis muscle function using the Frontalis Function Scale (FFS) compared to baseline, as assessed by the blinded evaluating investigator, at each visit.; The Frontalis Function Scale (FFS) scale ranges from a score of 0 to 3, and a higher score indicates greater reduction of forehead movement during maximal brow raise.	270 days

External Links

•   Jeuveau Highlights of Prescribing Information.